Spots Global Cancer Trial Database for RAD001 in Advanced Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: RAD001 in Advanced Sarcoma
Official Title: A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas
Study ID: NCT01830153
Interventions
Study Description
Brief Summary: This trial intends to test the efficacy and safety of RAD001 in patients with advanced sarcoma who failed to conventional chemotherapy.
Detailed Description: This multicenter, phase II trial evaluated the efficacy and safety of everolimus in patients with metastatic or recurrent bone and soft tissue sarcoma after failure of anthracycline and/or ifosfamide.
Eligibility
Minimum Age: 17 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Asan Medical Center, University of Ulsan College of Medicine, Seoul, N/A = Not Applicable, Korea, Republic of
Yeongnam University College of Medicine, Daegu, , Korea, Republic of
Chungnam National University Hospital, Daejeon, , Korea, Republic of
Seoul National University Hospital, Seoul, , Korea, Republic of
Yonsei Cancer Center, Seoul, , Korea, Republic of
Korea University, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
Contact Details
Name: Jin-Hee Ahn, MD, PhD
Affiliation: Asan Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
